Daily Endocrinology Research Analysis
Analyzed 103 papers and selected 3 impactful papers.
Summary
Analyzed 103 papers and selected 3 impactful articles.
Selected Articles
1. Patient-derived organoids reveal ductal dysfunction and CFTR-modulator responses in chronic pancreatitis.
This study established a 37-patient PDO platform for chronic pancreatitis, identifying three molecular subtypes and widespread CFTR dysfunction, including in cases without CFTR mutations. Clinically available CFTR modulators restored CFTR function and dampened mitogenic/inflammatory signaling, positioning CFTR modulation as a precision therapeutic strategy in chronic pancreatitis.
Impact: Provides a mechanistic and actionable precision-medicine framework for chronic pancreatitis, a disease with limited disease-modifying options, using patient-derived organoids that predict drug response.
Clinical Implications: CFTR modulators, already approved for cystic fibrosis, may be repurposed for selected chronic pancreatitis patients with demonstrated CFTR dysfunction, guiding individualized therapy using organoid testing.
Key Findings
- Developed a PDO platform from 37 chronic pancreatitis patients capturing inflammation-associated molecular features.
- Identified three CP molecular subtypes independent of etiology.
- Discovered widespread CFTR dysfunction in ~50% of PDOs, including those with wild-type CFTR.
- Clinically available CFTR modulators restored CFTR function and reduced mitogenic and inflammatory signaling in PDOs.
Methodological Strengths
- Use of patient-derived organoids enabling functional and transcriptomic assessment directly from human disease tissue.
- Multi-omic profiling linked to pharmacologic rescue with clinically available modulators.
Limitations
- Ex vivo organoid responses may not fully predict in vivo clinical efficacy and safety.
- Long-term clinical outcomes with CFTR modulators in chronic pancreatitis were not assessed.
Future Directions: Prospective, organoid-guided clinical trials to test CFTR modulators in molecularly selected chronic pancreatitis subgroups; exploration of combination strategies to modulate inflammatory and mitogenic pathways.
Chronic pancreatitis (CP) affects ∼3 million people worldwide, yet altering the course of the disease is challenging. We developed a patient-derived organoid (PDO) platform to investigate the molecular pathogenesis of this disease and identify therapeutic strategies. We generated 37 PDOs from patients with idiopathic, hereditary, and alcohol-related CP with a high genetic concordance. PDOs retained inflammation-associated transcriptional and proteomic features. Transcriptomic profiling revealed three molecular su
2. Ketone Bodies Derived From Medium-Chain Triglycerides Support Brain Metabolism and Function Under Hypoglycemia in Type 1 Diabetes Mellitus.
In T1D, exogenous BHB contributed more to brain metabolism during hypoglycemic clamps than in healthy controls, and medium-chain triglyceride supplementation improved working memory and regional brain activation during hypoglycemia without altering counterregulatory hormones. These data support dietary ketone strategies to protect the brain from hypoglycemia-induced dysfunction.
Impact: Provides mechanistic human evidence and a randomized dietary intervention showing that ketone availability can preserve cognitive function during hypoglycemia in T1D.
Clinical Implications: Medium-chain triglyceride supplementation may be considered as an adjunct strategy to mitigate hypoglycemia-related cognitive impairment in T1D, pending larger and longer-term trials and individualized dietary counseling.
Key Findings
- During hypoglycemic clamps, infused β-hydroxybutyrate contributed more to brain metabolism in T1D than in healthy controls.
- Randomized dietary MCT supplementation improved working memory performance and increased regional brain activation during hypoglycemia in T1D.
- Counterregulatory hormone responses to hypoglycemia were unaffected by MCT supplementation.
Methodological Strengths
- Combined first-in-human mechanistic MRS with a randomized dietary intervention.
- Objective cognitive and neuroimaging endpoints during controlled hypoglycemia.
Limitations
- Sample sizes and intervention duration were not reported in the abstract; likely small and short-term.
- Generalizability to diverse T1D populations and free-living conditions remains to be established.
Future Directions: Larger, multicenter RCTs assessing long-term cognitive outcomes, safety, and adherence to MCT supplementation; comparison with other ketone strategies (exogenous ketones, ketogenic diets) and integration with automated insulin delivery.
UNLABELLED: Impaired cognitive function caused by insulin-induced hypoglycemia is a complication of type 1 diabetes mellitus (T1DM) for which no protective strategies are currently available. In this first-in-human mechanistic study using magnetic resonance spectroscopy, the direct contribution of the infused ketone β-hydroxybutyrate (BHB) to brain metabolism during clamped hypoglycemia was greater in participants with T1DM than healthy participants. In a randomized dietary intervention trial of participa
3. SGLT2 inhibitors enhance ketogenesis by acting as allosteric activators of the mitochondrial enzyme HMGCS2.
This mechanistic study demonstrates that SGLT2 inhibitors directly and allosterically activate mitochondrial HMGCS2, enhancing hepatic ketogenesis. The finding provides a plausible unifying mechanism linking SGLT2 inhibitors to cardiorenal benefits observed clinically.
Impact: Identifies a first-in-class direct enzymatic target (HMGCS2) for SGLT2 inhibitors, reframing their systemic metabolic effects beyond glycosuria.
Clinical Implications: Supports careful monitoring of ketosis risk and suggests that modulating ketogenesis may be integral to cardiorenal benefit; may inform patient selection, dietary counseling, and combination strategies to harness benefits while mitigating ketoacidosis risk.
Key Findings
- SGLT2 inhibitors directly activate HMGCS2, the rate-limiting mitochondrial enzyme in ketogenesis, via allosteric mechanisms.
- Enhanced ketone production provides a mechanistic link to observed cardiac and renal benefits of SGLT2 inhibitors.
Methodological Strengths
- Clear mechanistic insight identifying a direct enzymatic target underlying systemic metabolic effects.
- Findings integrate with established clinical observations of cardiorenal benefit.
Limitations
- Preclinical mechanistic focus; clinical validation of the pathway’s contribution to outcomes is needed.
- Experimental details and sample sizes are not provided in the abstract.
Future Directions: Clinical and translational studies quantifying ketone dynamics, HMGCS2 activity, and outcomes in SGLT2 inhibitor users; exploration of dietary and pharmacologic modulators of ketogenesis to optimize benefit–risk.
SGLT2 inhibitors boost ketone production by directly activating a liver enzyme, revealing a new mechanism that may contribute to their heart and kidney benefits.